Systematic Review Reveals Significant Disparities in US Biologics Access Across Immunology Specialties
核心洞察
A comprehensive systematic review of 21 studies found that disparities in biologics (搜索) access were inconsistently studied across rheumatology, dermatology, and gastroenterology, with only 38% of studies evaluating clinical or economic outcomes.
Key factors associated with reduced biologics (搜索) access included insurance type (particularly Medicaid (搜索)), Black, Hispanic, or Asian race and ethnicity, high out-of-pocket costs, and prior authorization requirements.
Patients experiencing biologics (搜索) access disparities faced worse clinical outcomes, including higher hospital admission and readmission rates, increased emergency department visits, and treatment delays.
A new systematic review published in the American Journal of Managed Care reveals significant disparities in access to biologic medications across immunology specialties in the United States, with certain patient populations facing substantial barriers to these life-changing treatments.
The comprehensive analysis, which examined 21 studies published between 2017 and 2023, found that disparities in biologics (搜索) access were inconsistently studied across rheumatology, dermatology, and gastroenterology. Notably, only 8 studies (38%) evaluated the clinical or economic outcomes associated with limited biologics access, highlighting a critical gap in understanding the real-world impact of these disparities.
Key Barriers to Biologics Access
The research identified several primary factors that consistently impede patient access to biologic therapies. Insurance type emerged as a significant barrier, with studies showing conflicting results regarding commercial versus public insurance coverage. Jin et al found that patients with commercial insurance were 87% more likely to initiate rheumatoid arthritis (搜索) treatment with biologic disease-modifying antirheumatic drugs (搜索) (bDMARDs (搜索)) compared to patients with Medicaid (搜索). However, other studies reported opposite findings, with some showing that Medicare (搜索) patients had higher odds of receiving bDMARDs versus those with commercial insurance.
Race and ethnicity represented another major access barrier. Eight studies across multiple specialties demonstrated that Black, Hispanic, or Asian patients were less likely to receive biologics (搜索) compared to White patients. In a claims study among Medicaid (搜索) patients, Black patients had 30% to 40% lower odds of initiating bDMARDs (搜索) for rheumatoid arthritis (搜索) treatment versus non-Hispanic White patients. Similar patterns emerged in dermatology, where Black patients were consistently less likely to receive or use biologics for psoriasis (搜索) treatment.
High out-of-pocket costs and prior authorization requirements created additional obstacles. More than 70% of participants in a dermatological survey study reported that high out-of-pocket costs were among the largest barriers to seeking psoriasis (搜索) treatment. Prior authorization processes proved particularly problematic, with one study finding that 100% of initial prior authorizations for biologics (搜索) were denied for patients with dermatological conditions, though this finding was based on limited records.
Clinical and Economic Consequences
The review revealed serious consequences for patients experiencing biologics (搜索) access disparities. The most frequently reported outcomes included higher hospital admission and readmission rates, increased emergency department visits, and treatment delays. A dermatology-focused literature review found that Black, Hispanic, Asian, or multiracial patients were more likely than White patients to be hospitalized for psoriasis (搜索), with increased hospitalization rates potentially indicating severe or inadequately managed disease.
In gastroenterology, patients with Medicaid (搜索) insurance demonstrated higher hospital and emergency department visit rates compared to those with other insurance types. Prior authorization delays resulted in clinical deterioration, with higher rates of worsening observed in patients who experienced delays in biologics (搜索) insurance approvals.
Addressing the Disparities
The systematic review identified several evidence-based solutions to improve biologics (搜索) access. Financial barriers could be addressed through clinician identification of patients experiencing financial hardship and enrollment in assistance programs. The development of biosimilars and expansion of drug formularies may help limit high out-of-pocket costs for patients while reducing expenses for healthcare systems.
Improving availability through case management could assist patients in navigating the healthcare system and reduce specialist wait times. Patient support programs have shown promise in improving both availability and access to biologic treatments by providing financial support, treatment regimen management, and reducing prescription abandonment rates.
Educational initiatives represent another crucial component. The FDA acknowledges patient and clinician education as key to improving biologics (搜索) accessibility. Public awareness campaigns using multiple outreach channels, along with enhanced health literacy materials, could help address knowledge gaps that contribute to access disparities.
Research Gaps and Future Directions
The review highlighted significant limitations in current research on biologics (搜索) access disparities. Key socioeconomic status data, including income, education, and patient occupation, are not commonly collected in studies. Many investigations focus on particular underrepresented groups rather than examining the complex interplay of multiple factors, potentially underestimating health disparity risks for patients facing multiple barriers.
The authors noted that diseases may be underdiagnosed and treatment patterns underreported for some groups, resulting in underestimation of disparities. Additionally, many studies were single-center evaluations, limiting generalizability of findings.
Implications for Healthcare Policy
The findings underscore the complex nature of healthcare disparities and the need for comprehensive approaches to address biologics (搜索) access barriers. The high cost of biologics, combined with complexities in the US healthcare system, creates affordability challenges that disproportionately affect certain populations.
Payer policies such as prior authorization requirements and co-pay accumulators and maximizers further complicate access. These barriers can lead to delayed treatment initiation and worse clinical outcomes, including disease progression, increased disability, and reduced health-related quality of life.
The research emphasizes that achieving equitable access to biologics (搜索) requires coordinated efforts across multiple stakeholders, including healthcare providers, payers, and policymakers. Multistakeholder collaborations and public-private partnerships should be considered as strategies for enhancing biologics treatment accessibility.
This systematic review represents the first comprehensive analysis of biologics (搜索) access disparities across immunology specialties, providing crucial insights for developing targeted interventions to ensure equitable access to these important medications for all patients with immunological conditions.